## Ron A A Matht

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1629441/ron-a-a-mathot-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

4,656 62 184 36 h-index g-index citations papers 196 4.8 5,423 5.39 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
184	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study) <i>TH Open</i> , <b>2022</b> , 6, e60-e69	2.7	
183	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial Journal of Dermatological Treatment, 2022, 1-5	2.8	0
182	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to	3	
181	The association between desmopressin exposure, FVIII response and side effects. <i>Haemophilia</i> , <b>2021</b> , 27, e506-e509	3.3	
180	Sedation With Midazolam After Cardiac Surgery in Children With and Without Down Syndrome: A Pharmacokinetic-Pharmacodynamic Study. <i>Pediatric Critical Care Medicine</i> , <b>2021</b> , 22, e259-e269	3	O
179	Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. <i>Blood Advances</i> , <b>2021</b> , 5, 1513-1522	7.8	0
178	Development and Validation of a Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Technique to Determine Levamisole in Plasma and Saliva. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 279-285	3.2	O
177	Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected Infection. <i>Antibiotics</i> , <b>2021</b> , 10,	4.9	2
176	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4408-4420	3.8	2
175	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1361-1372	6.2	2
174	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with -Mutated Solid Tumors. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
173	Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. <i>British Journal of Haematology</i> , <b>2021</b> , 194, 423-432	4.5	1
172	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	1
171	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology,the</i> , <b>2021</b> , 8, e492-e	5 <b>62</b> .6	2
170	Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. <i>Haematologica</i> , <b>2021</b> , 106, 1254-1261	6.6	6
169	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 106-118	3.8	7
168	Why we should sample sparsely and aim for a higher target: Lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 1234-1242	3.8	1

## (2020-2021)

167	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2602-2613	3.8	4
166	Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 352-363	9.5	4
165	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 145-154	2.4	19
164	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. <i>Clinical Pharmacokinetics</i> , <b>2021</b> , 60, 1-16	6.2	2
163	Transcapillary escape rate of I-albumin in relation to timing of blood sampling: the need for standardization. <i>EJNMMI Radiopharmacy and Chemistry</i> , <b>2021</b> , 6, 9	5.8	
162	Wound infection following implant removal of foot, ankle, lower leg or patella; alprotocol for a multicenter randomized controlled trial investigating the (cost-)effectiveness of 2lg of prophylactic cefazolin compared to placebo (WIFI-2 trial). <i>BMC Surgery</i> , <b>2021</b> , 21, 69	2.3	
161	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
160	In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 1193-1200	2.8	1
159	Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> ,	3.2	1
158	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , <b>2021</b> , 27, 974-983	3.3	O
157	Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. <i>Blood Advances</i> , <b>2021</b> , 5, 4314-4325	7.8	O
156	Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1309-1319	6.1	5
155	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 731-740	7	3
154	Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 3222-3231	15.4	4
153	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. <i>Acta Oncolgica</i> , <b>2020</b> , 59, 1028-1035	3.2	8
152	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1056-1065	7	2
151	Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 1098-1106	6.1	3
150	Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1620-1631	3.8	5

149	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 880-885	3.2	1
148	Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. <i>Molecular Oncology</i> , <b>2020</b> , 14, 704-720	7.9	4
147	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P /Humate P treatment in von Willebrand disease patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 295-305	15.4	4
146	Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. <i>Oncologist</i> , <b>2020</b> , 25, e1274-e1279	5.7	9
145	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 634-639	8.7	24
144	Pharmacokinetics and population pharmacokinetics in pediatric oncology. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28132	3	3
143	Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 295-301	3.2	6
142	The effects of fasting on drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 79-85	5.5	9
141	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 289-294	3.2	7
140	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 462-471	2.2	21
139	Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 106166	14.3	3
138	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1407-1416	7	2
137	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. <i>MAbs</i> , <b>2020</b> , 12, 1795492	6.6	6
136	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 747-757	7	4
135	Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients. <i>Pharmaceutical Research</i> , <b>2020</b> , 37, 171	4.5	1
134	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 997-1006.e6	13.3	51
133	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2019</b> , 46, 543-551	2.7	3
132	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 700-706	2.4	10

#### (2018-2019)

131	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. <i>BMJ Open</i> , <b>2019</b> , 9, e022719	3	2
130	External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	24
129	Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery. <i>BMJ Case Reports</i> , <b>2019</b> , 12,	0.9	1
128	Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 154	4 <sup>3</sup> 1 <sup>8</sup> 551	18
127	Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	3
126	Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy?. <i>Journal of Neurotrauma</i> , <b>2019</b> , 36, 111-117	5.4	11
125	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 15-37	6.2	46
124	Differential effects of a 40-hour fast and bile acid supplementation on human GLP-1 and FGF19 responses. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2019</b> , 317, E494-E502	6	4
123	832 Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial. <i>Gastroenterology</i> , <b>2019</b> , 156, S-180-S-181	13.3	2
122	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. <i>Haemophilia</i> , <b>2019</b> , 25, 960-968	3.3	3
121	Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4086-4086	2.2	7
120	Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2019</b> , 90, 97-104	4.3	5
119	Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study). <i>BMJ Open</i> , <b>2019</b> , 9, e027011	3	10
118	Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. <i>BMJ Paediatrics Open</i> , <b>2019</b> , 3, e000520	2.4	2
117	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 192-212	3.2	5
116	Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1620-1629	5.1	15
115	CNS penetration of ART in HIV-infected children. Journal of Antimicrobial Chemotherapy, 2018, 73, 484-	189	12
114	Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely Ill Sub-Saharan African Patient Population. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1261-1269	11.6	2

113	An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 523-527	4.5	8
112	Evaluation of a System-Specific Function To Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	6
111	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 202-211	3.2	15
110	A phase lb study of everolimus combined with metformin for patients with advanced cancer. <i>Investigational New Drugs</i> , <b>2018</b> , 36, 53-61	4.3	13
109	Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 320-330	3.8	13
108	Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2018</b> , 43, 251-257	2.7	6
107	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 621-629	7	5
106	Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. <i>European Journal of Drug Metabolism and</i>	2.7	5
105	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study  Journal of Clinical Oncology, 2018, 36, 4057-4057	2.2	3
104	Positioning extended half-life concentrates for future use: a practical proposal. <i>Haemophilia</i> , <b>2018</b> , 24, e369-e372	3.3	1
103	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 53	5 <i>-</i> 548	30
102	Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1227-1239	3.8	19
101	Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 1231-1244	6.2	16
100	Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1701-1712	3.8	15
99	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> , <b>2017</b> , 102, 552-561	6.6	10
98	Golimumab for moderate to severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 401-406	4.2	6
97	Quantitative Method for Simultaneous Analysis of Acetaminophen and 6 Metabolites. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 172-179	3.2	3
96	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours. <i>BMJ Open</i> , <b>2017</b> , 7, e014961	3	55

## (2016-2017)

95	Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 49, 204-211	14.3	23	
94	Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	9	
93	Pharmacokinetics of S-ketamine during prolonged sedation at the pediatric intensive care unit. <i>Paediatric Anaesthesia</i> , <b>2017</b> , 27, 1098-1107	1.8	5	
92	Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study. <i>BMC Research Notes</i> , <b>2017</b> , 10, 671	2.3	3	
91	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. <i>Drug Delivery</i> , <b>2017</b> , 24, 1801-1810	7	4	
90	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. <i>Thrombosis Research</i> , <b>2017</b> , 160, 76-82	8.2	10	
89	Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 522-530	3.2	16	
88	Survival analysis of a phase IB/II study of everolimus and metformin for patients with advanced cancer <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e14020-e14020	2.2		
87	Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	5	
86	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. <i>Haematologica</i> , <b>2016</b> , 101, 1159-1169	6.6	31	
85	Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. <i>Pediatric Critical Care Medicine</i> , <b>2016</b> , 17, 930-938	3	19	
84	Quantitative Method for Simultaneous Analysis of a 5-Probe Cocktail for Cytochrome P450 Enzymes. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 761-768	3.2	9	
83	Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 1067-77	3.8	23	
82	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 697-709	6.2	20	
81	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 251-8.e1-2	6.9	125	•
80	Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e21506-e21506	2.2		
79	Phase I study of everolimus combined with metformin for patients with advanced cancer <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14088-e14088	2.2		
78	A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects. Expert Opinion on Drug Metabolism and Toxicology, <b>2016</b> , 12, 715-20	5.5	10	

77	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1129-43	6.2	24
76	Prevalence and Implications of Abnormal Laboratory Results in Patients in the Terminal Phase of Life. <i>Journal of Palliative Medicine</i> , <b>2016</b> , 19, 822-9	2.2	7
75	Short-term fasting alters cytochrome P450-mediated drug metabolism in humans. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 819-28	4	21
74	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 839-47	21.7	251
73	Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. <i>Gastroenterology</i> , <b>2015</b> , 149, 350-5.e2	13.3	254
72	Medication use during end-of-life care in a palliative care centre. <i>International Journal of Clinical Pharmacy</i> , <b>2015</b> , 37, 767-75	2.3	50
71	The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 639-4	14 <sup>7</sup>	20
70	Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics. <i>Blood</i> , <b>2015</b> , 126, 2501-2501	2.2	1
69	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. <i>Blood</i> , <b>2015</b> , 126, 3510-3510	2.2	2
68	Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients. <i>Blood</i> , <b>2015</b> , 126, 1281	-1281	
67	A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the</i>	3.2	50
66	Biomedical and Life Sciences, <b>2014</b> , 951-952, 110-8 Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 619-29	2.9	31
65	Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. <i>BMC Pediatrics</i> , <b>2014</b> , 14, 193	2.6	20
64	Clinical evaluation of vancomycin dosage in pediatric oncology patients. <i>Pediatric Infectious Disease Journal</i> , <b>2014</b> , 33, 731-3	3.4	5
63	A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4021-4021	2.2	3
62	A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 52, 653-62	2	2
61	Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: <b>T</b> ackling a Moving Target[ <b>(D</b> )PTI-CLOT[ <b>S</b> tudies). <i>Blood</i> , <b>2014</b> , 124, 5031-5031	2.2	
60	Effect of hypothermia and extracorporeal life support on drug disposition in neonates. <i>Seminars in Fetal and Neonatal Medicine</i> , <b>2013</b> , 18, 23-7	3.7	13

## (2010-2013)

59	Pharmacokinetic-pharmacodynamic modeling of the antihypertensive effect of eprosartan in Black and White hypertensive patients. <i>Clinical Pharmacokinetics</i> , <b>2013</b> , 52, 793-803	6.2	6
58	Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 149-54	27.4	146
57	Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial population. <i>American Journal of Hypertension</i> , <b>2013</b> , 26, 1103-13	2.3	7
56	Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , <b>2012</b> , 16, 613-8	1.8	36
55	Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. <i>BMC Pediatrics</i> , <b>2012</b> , 12, 45	2.6	36
54	Acute liver failure after recommended doses of acetaminophen in patients with myopathies. <i>Critical Care Medicine</i> , <b>2011</b> , 39, 678-82	1.4	17
53	Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2011</b> , 6, 656-63	6.9	51
52	Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 353-62	12.9	46
51	Ultrafast selective quantification of methotrexate in human plasma by high-throughput MALDI-isotope dilution mass spectrometry. <i>Bioanalysis</i> , <b>2011</b> , 3, 1369-78	2.1	17
50	Sample collection, biobanking, and analysis. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 205, 203-1	7 3.2	4
50	Sample collection, biobanking, and analysis. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 205, 203-1.  High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63	7 3.2	171
	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term		
49	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal	4.3	171
49	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1734-41  Enhanced paracetamol clearance with molecular adsorbents recirculating system (MARSI) in	4.3	171 45
49 48 47	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1734-41  Enhanced paracetamol clearance with molecular adsorbents recirculating system (MARSII) in severe autointoxication. <i>Blood Purification</i> , <b>2010</b> , 30, 118-9  Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal	4·3 5·9 3·1	<ul><li>171</li><li>45</li><li>9</li></ul>
49 48 47 46	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1734-41  Enhanced paracetamol clearance with molecular adsorbents recirculating system (MARSII) in severe autointoxication. <i>Blood Purification</i> , <b>2010</b> , 30, 118-9  Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 407-19	4·3 5·9 3.1 6.2	<ul><li>171</li><li>45</li><li>9</li><li>56</li></ul>
49 48 47 46 45	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2757-63  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1734-41  Enhanced paracetamol clearance with molecular adsorbents recirculating system (MARSII) in severe autointoxication. <i>Blood Purification</i> , <b>2010</b> , 30, 118-9  Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 407-19  Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , <b>2010</b> , 95, F109-14	4·3 5·9 3·1 6·2	<ul><li>171</li><li>45</li><li>9</li><li>56</li><li>46</li></ul>

41	Quantification of midazolam, morphine and metabolites in plasma using 96-well solid-phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , <b>2010</b> , 24, 969-76	1.7	18
40	Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2010</b> , 878, 675-81	3.2	28
39	Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2005-13	5.9	39
38	Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 75-80	5.9	45
37	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , <b>2009</b> , 36, 541-64	2.7	61
36	Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2009</b> , 48, 463-76	6.2	28
35	Limited sampling strategies for therapeutic drug monitoring of mycophenolate mofetil therapy in patients with autoimmune disease. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 382-90	3.2	27
34	Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 549-56	3.2	22
33	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 626-34	1.9	63
32	Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 351-9	3.2	47
31	Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 585-91	3.2	24
30	Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. <i>Paediatric Anaesthesia</i> , <b>2008</b> , 18, 582-92	1.8	40
29	Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 752-60	3.8	67
28	Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2008</b> , 47, 827-38	6.2	66
27	Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 1345-50	5.9	15
26	Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. <i>Oncologist</i> , <b>2007</b> , 12, 291-300	5.7	51
25	Time-dependent clearance of mycophenolic acid in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 741-52	3.8	56
24	Influence of ketoconazole on the fecal and urinary disposition of docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 60, 569-79	3.5	13

### (2005-2007)

23	Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3049-55	5.9	40
22	Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1368-74	4.6	16
21	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2007</b> , 3, 251-61	5.5	31
20	Time-dependent clearance decrements of fluvoxamine in depressed inpatients: a clinical evaluation. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 231-3	1.7	1
19	Alternative drug formulations of docetaxel: a review. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 95-103	2.4	159
18	Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 353-60	3.2	36
17	Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. <i>Cancer Biology and Therapy</i> , <b>2006</b> , 5, 833-9	4.6	33
16	Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 871-80	12.7	162
15	Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2006</b> , 57, 732-40	5.1	43
14	Individualization of mycophenolate mofetil dose in renal transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 361-76	4	18
13	Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 31-4	3.2	25
12	Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. <i>Anesthesiology</i> , <b>2006</b> , 105, 1135-46	4.3	48
11	Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. <i>Pediatric Infectious Disease Journal</i> , <b>2006</b> , 25, 538-43	3.4	10
10	Population pharmacokinetics of mycophenolic acid in renal transplant recipients. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 1083-96	6.2	81
9	Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 163-7	3.2	27
8	Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. <i>American Journal of Transplantation</i> , <b>2005</b> , 5, 987-94	8.7	259
7	Estimation of the glomerular filtration rate in children: which algorithm should be used?. <i>Pediatric Nephrology</i> , <b>2005</b> , 20, 1769-75	3.2	28
6	Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1. <i>Digestive Diseases and Sciences</i> , <b>2005</b> , 50, 1804-6	4	5

5	Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2237-44	12.9	35
4	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 545-56	6.1	128
3	Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 620-5	3.2	37
2	Optimal sampling strategies to assess inulin clearance in children by the inulin single-injection method. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 1170-9	5.5	25
1	Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 63-73	3.2	180